" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Roche Launches Additional Test for Improved Management of Epithelial Ovarian Cancer Patients

Published: Wednesday, November 14, 2012
Last Updated: Wednesday, November 14, 2012
Bookmark and Share
Automated assay offers efficient testing, expands company's tumor marker portfolio on integrated platforms.

Roche announced today the U.S. market availability of the Elecsys HE4 assay, an FDA approved test used in monitoring patients with ovarian cancer. The HE4 test is used as an aid in monitoring the recurrence or progressive disease in patients with epithelial ovarian cancer.

Studies like K Huhtinen et al (2009) show that HE4 shows a high specificity to ovarian cancer over that of CA 125 alone. Both HE4 and CA 125 together, rather than either of them alone, provides a more accurate tool for differential diagnosis of patients with ovarian cancer and ovarian endometriotic cysts from healthy subjects.

"As a leader in oncology, Roche is committed to providing reliable tests that will enable physicians to deliver the best possible care to their patients," said Randy Pritchard, vice president of marketing at Roche Diagnostics Corporation. "The addition of the Elecsys HE4 assay further strengthens our tumor biomarker menu and means healthcare providers now have another tool to give them greater confidence in monitoring patients with ovarian cancer."

About the Test
The Elecsys HE4 assay is an immunoassay for the quantitative determination of HE4 in human serum and plasma. The assay is used as an aid in monitoring the recurrence or progressive disease in patients with epithelial ovarian cancer. Serial testing for patient HE4 assay values should be used in conjunction with other clinical findings used for monitoring ovarian cancer. The immunoassay is intended for use with Roche's electrochemiluminescence (ECL) technology, a highly sensitive light detection system that provides excellent low-end sensitivity and broad dynamic measuring ranges. The test is approved for use on the Elecsys 2010, cobas e 411, cobas e 601, cobas e602 and MODULAR ANALYTICS E170 analyzers.

About ovarian cancer
Ovarian cancer is the fourth most common cause of cancer-related death in women worldwide. It is the most lethal form of gynecological cancer, and potentially curable if diagnosed early and treated by surgeons familiar with the management of ovarian cancer. However, the symptoms of ovarian cancer are related to the presence of adnexal masses and are often vague and unspecific. Thus 70-75% of ovarian cancers are detected at a late stage. According to the International Agency for Research on Cancer, the 5 year survival rate of ovarian cancer patients is 46%. However, if the disease is diagnosed early, the survival rate increases up to 94%.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche Acquires GeneWEAVE to Strengthen Offerings in Microbiology Diagnostics
GeneWEAVE’s Smarticles technology enhances Roche’s role in fighting drug-resistant bacteria.
Friday, August 14, 2015
Roche Acquires Ariosa Diagnostics
Acquisition will see Roche enter the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets.
Wednesday, December 03, 2014
Roche Receives FDA Clearance for Strep A Test
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection.
Friday, November 14, 2014
Roche to Invest in New Diagnostic Manufacturing Facility in China
The facility will address Asia Pacific’s growing demand for diagnostics.
Monday, November 10, 2014
Roche Invests For The Future In Its Basel Site
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development.
Thursday, October 23, 2014
Roche, Garvan Institute Epigenomic Partnership
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
Wednesday, August 20, 2014
Roche Acquires Genia Technologies for up to $350M
Acquisition of the privately held Genia to strengthen Roche's next generation sequencing pipeline.
Monday, June 02, 2014
Roche Acquires IQuum
Acquisition will allow Roche to quickly enter the point of care segment of molecular diagnostics.
Monday, April 07, 2014
Roche, Discuva Collaborate
Companies join forces to combat life-threatening infections caused by multi-drug resistant bacteria.
Friday, February 28, 2014
Roche Signs Licensing Agreement with Sysmex Inostics
Under the terms of the agreement, Roche grants Sysmex a worldwide, non-exclusive, royalty-bearing license.
Friday, February 21, 2014
FDA Approves New Streamlined Workflow Option for Roche's Cobas HPV Test
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow.
Friday, June 28, 2013
Change to the Roche Corporate Executive Committee
Appointment of John C. Reed as Head of Roche Pharma Research and Early Development.
Monday, January 28, 2013
Kingston Hospital Delivers Point of Care Testing Excellence
Roche cobas® b 221 blood gas analysers and Roche POC IT connectivity bring improvements for patients and staff alike.
Tuesday, July 03, 2012
Roche and Life Technologies Corporation Sign New PCR IVD Licenses
Companies announced that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.
Thursday, February 23, 2012
Roche Enters Strategic Alliance with Technoclone to Expand Reagent Portfolio for Coagulation Diagnostics Line Targeted for US and Canada in 2014
Focus on reagents for thrombosis and cardiovascular diagnostics complements Roche plans to introduce comprehensive line of coagulation analyzers for hospital and reference labs
Wednesday, February 01, 2012
Scientific News
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Antibiotic Susceptibility Testing
A team of biologists and biomedical researchers at UC San Diego has developed a new method to determine if bacteria are susceptible to antibiotics within a few hours, an advance that could slow the appearance of drug resistance and allow doctors to more rapidly identify the appropriate treatment for patients with life threatening bacterial infections.
Spotlight on Acoustic Liquid Handling
Journal of Laboratory Automation special issue highlights how acoustic liquid handling enables breakthrough innovations.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!